AIM: To assess changes in motor function in patients with Duchenne muscular dystrophy using the Motor Function Measure (MFM). METHOD: Three studies were performed. Two studies included only physiotherapy-treated patients, with 13 patients (males mean age 11y 7mo, SD 1y 10mo, range 8-14y) in the 3-month study and 41 patients (males mean age 14y 1mo, SD 5y 5mo, range 6-32y) in the 1-year study. A third study compared 12 patients treated with steroids with 12 age- and motor-function-matched untreated patients (males mean age of treated patients 10y 2mo, SD 2y 2mo range 6-14) over a 12-month period. RESULTS: Over 3 months, the MFM D1 subscore (standing and transfers) decreased significantly (-4.7%; p<0.01). Over 1 year, all MFM subscores decreased significantly: -4.9% for D1 (p<0.01); -7.7% for D2 (axial and proximal motor capacity; p<0.01); -4.3% for D3 (distal motor capacity; p=0.03); and -5.8% for the total score (p<0.01). A threshold value for loss of ambulation and a predictive value 1 year before loss were estimated (total score 70% and D1 subscore 40%). Compared with the controls, patients treated with steroids had more stable total scores (-0.59 vs -5.87; p=0.02) and D2 subscores (0.98 vs -8.50; p<0.01). INTERPRETATION: These results support the use of the MFM in everyday patient management to prepare for loss of ambulation and in clinical trials to follow up patients receiving various treatments.
AIM: To assess changes in motor function in patients with Duchenne muscular dystrophy using the Motor Function Measure (MFM). METHOD: Three studies were performed. Two studies included only physiotherapy-treated patients, with 13 patients (males mean age 11y 7mo, SD 1y 10mo, range 8-14y) in the 3-month study and 41 patients (males mean age 14y 1mo, SD 5y 5mo, range 6-32y) in the 1-year study. A third study compared 12 patients treated with steroids with 12 age- and motor-function-matched untreated patients (males mean age of treated patients 10y 2mo, SD 2y 2mo range 6-14) over a 12-month period. RESULTS: Over 3 months, the MFM D1 subscore (standing and transfers) decreased significantly (-4.7%; p<0.01). Over 1 year, all MFM subscores decreased significantly: -4.9% for D1 (p<0.01); -7.7% for D2 (axial and proximal motor capacity; p<0.01); -4.3% for D3 (distal motor capacity; p=0.03); and -5.8% for the total score (p<0.01). A threshold value for loss of ambulation and a predictive value 1 year before loss were estimated (total score 70% and D1 subscore 40%). Compared with the controls, patients treated with steroids had more stable total scores (-0.59 vs -5.87; p=0.02) and D2 subscores (0.98 vs -8.50; p<0.01). INTERPRETATION: These results support the use of the MFM in everyday patient management to prepare for loss of ambulation and in clinical trials to follow up patients receiving various treatments.
Authors: William D Rooney; Yosef A Berlow; William T Triplett; Sean C Forbes; Rebecca J Willcocks; Dah-Jyuu Wang; Ishu Arpan; Harneet Arora; Claudia Senesac; Donovan J Lott; Gihan Tennekoon; Richard Finkel; Barry S Russman; Erika L Finanger; Saptarshi Chakraborty; Elliott O'Brien; Brendan Moloney; Alison Barnard; H Lee Sweeney; Michael J Daniels; Glenn A Walter; Krista Vandenborne Journal: Neurology Date: 2020-03-17 Impact factor: 9.910
Authors: Sydney Pettygrove; Zhenqiang Lu; Jennifer G Andrews; F John Meaney; Daniel W Sheehan; Elinora T Price; Deborah J Fox; Shree Pandya; Lijing Ouyang; Susan D Apkon; Zoe Powis; Christopher Cunniff Journal: Muscle Nerve Date: 2014-06 Impact factor: 3.217
Authors: Katherine G Meilleur; Minal S Jain; Linda S Hynan; Ching-Yi Shieh; Eunice Kim; Melissa Waite; Michelle McGuire; Courtney Fiorini; Allan M Glanzman; Marion Main; Kristy Rose; Tina Duong; Roxanna Bendixen; Melody M Linton; Irene C Arveson; Carmel Nichols; Kelly Yang; Kenneth H Fischbeck; Kathryn R Wagner; Kathryn North; Ami Mankodi; Christopher Grunseich; Elizabeth J Hartnett; Michaele Smith; Sandra Donkervoort; Alice Schindler; Angela Kokkinis; Meganne Leach; A Reghan Foley; James Collins; Francesco Muntoni; Anne Rutkowski; Carsten G Bönnemann Journal: Neuromuscul Disord Date: 2014-09-28 Impact factor: 4.296
Authors: James J Starc; Ryan A Moore; Mantosh S Rattan; Chet R Villa; Zhiqian Gao; Wojciech Mazur; John L Jefferies; Michael D Taylor Journal: Pediatr Cardiol Date: 2017-07-31 Impact factor: 1.655